BLOG

Fierce-Pharma

Calliditas, with a fresh approval for Tarpeyo in hand, launches IgA kidney disease education campaigN

Swedish biotech Calliditas is going all-in when it comes to firsts: After getting the first drug specifically approved for immunoglobulin A (IgA) nephropathy last year, it’s now running the first educational campaign for the disease amid the first-ever IgAN Awareness Day.